Search Results

November 2021 Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID -19 and Other Antibody Therapeutics for Difficult to Treat Diseases "Nov 15, 2021 -- Executive Leadership

December 2021 "Early-stage studies of COVID-19 treatments from the likes of Vir Biotechnology Inc. and Sotrovimab is the first monoclonal antibody showing preclinical efficacy against all COVID-19 variants

August 2022 "Cardiovascular diseases (CVDs) represent the leading cause of death globally.

April 2022 "By Sophie Bradley | Apr 12, 2022 Summary Sophie Bradley, Translational Sciences Associate Director at Sosei Heptares, recently presented at the Keystone Symposia GPCR Conference, a summary of work performed both at Sosei Heptares and Glasgow University characterizing the role of the muscarinic M1 receptor in cognitive and neurodegenerative disorders and the potential therapeutic benefit of muscarinic M1 selective ligands." Read more at the source #DrGPCR #GPCR #IndustryNews

October 2022 "Alzheimer's disease (AD) is the most common dementia in the elderly and its increasing Despite a better understanding of the disease, the current mainstay of treatment cannot modify pathogenesis suggests adenosine G protein-coupled receptors (GPCRs) are promising therapeutic targets for Alzheimer's disease In this review, we provide an accessible summary of the literature on Alzheimer's disease and the therapeutic

August 2022 "Alzheimer's disease (AD) is the most common dementia in the elderly and its increasing prevalence Despite a better understanding of the disease, the current mainstay of treatment cannot modify pathogenesis suggests adenosine G protein-coupled receptors (GPCRs) are promising therapeutic targets for Alzheimer's disease In this review, we provide an accessible summary of the literature on Alzheimer's disease and the therapeutic

September 2022 "Parkinson’s disease (PD) as a progressive neurodegenerative disorder arises from multiple

chemotaxis of leukocytes, especially neutrophils, during inflammation, a key process in cardiovascular disease

chemotaxis of leukocytes, especially neutrophils, during inflammation, a key process in cardiovascular disease

NETs were also detected in thrombotic lesions in several disease backgrounds, pointing towards a role In light of the current COVID-19 pandemic, the topic of immunothrombosis has become more relevant than ever, as a majority of COVID-19 patients display thrombi in the lung capillaries and other vascular between platelets and NETs and the potential of this alliance to influence the course of inflammatory diseases

pathways, are leading to the development of drugs with superior efficacy and reduced side effects in heart disease Although GPCRs are implicated in the pathophysiology of Alzheimer's disease (AD), biased GPCR signaling

normal glutamate transmission has been implicated in a variety of neurodegenerative and neuropsychiatric diseases contribution of mGluR2 and mGluR3 to the pathophysiology of some neurodegenerative and neuropsychiatric diseases including Amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, Parkinson's diseases

October 2022 Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived diabetes (T2DM) is provoking an important socioeconomic burden mainly in the form of cardiovascular disease

We have 19 GPCR papers, six industry news, two events, and two job ads. A Perspective on Class C GPCR Based Genetically Encoded Biosensors Emergence of lumpy skin disease virus April 5 - 10, 2024 | AACR Annual Meeting May 13 - 17, 2024 | 20th Annual PEGS Boston Summit May 16 - 19

GPCR-related genes analysis Reviews, GPCRs, and more GPR56, an Adhesion GPCR with Multiple Roles in Human Diseases

17, 2023 | MPGPCR Conference November 20 - 23, 2023 | ASCEPT Annual Scientific Meeting January 16 - 19 - 23, 2024 | Endocrine Metabolic GPCRs May 13 - 17, 2024 | 20th Annual PEGS Boston Summit May 16 - 19

Specialized Pro-resolving Lipid Mediators and Resolution of Viral Diseases. Industry News Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim

August 2022 "Several G-protein coupled receptors (GPCR) are upregulated in Alzheimer's Disease (AD),

and Immunology Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases (May 14 - 19, 2023) 8th and final ERNEST Meeting in Crete. (May 3 - 7, 2023).

(May 14 - 19, 2023) 8th and final ERNEST Meeting in Crete. (May 3 - 7, 2023).

focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases

Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease Statistically Significant Reduction in Chorea Movements (p < 0.0001) as Measured by the Unified Huntington's Disease inhibitor being investigated as a once-daily treatment in adults with chorea associated with Huntington disease met the primary endpoint of reduction in severity of chorea, the cardinal motor feature in Huntington disease , as measured by change in the Unified Huntington's Disease Rating Scale (UHDRS®) Total Maximal Chorea

Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare diseases "29/06/2022 Confo Therapeutics, founded in 2015 as a spin-off from VIB and VUB, announced today that

Acquired hypocalciuric hypercalcemia (AHH) is a rare disease caused by calcium-sensing receptor (CaSR follows: (a) elderly (74-87 years at diagnosis), (b) male, (c) unexpectedly showed no other autoimmune diseases

Dear GPCR Enthusiasts , Get ready for an exciting learning experience with our newly updated Principles of Pharmacology I & II  courses! We've refreshed the schedule and can’t wait for you to join us on these new dates. New Course Dates: Principles of Pharmacology I :  October 3, 10, 17, 24 (four sessions) Principles of Pharmacology II :  October 31, November 7, 14, 21, December 5 (five sessions) Courses Highlights Act Fast: Don’t miss this incredible opportunity to immerse yourself in the  Principles of Pharmacology I & II BUNDLE . Grab this chance to deepen your understanding of pharmacology and take your knowledge to the next level! Secure your spot today and elevate your expertise! Premium members enjoy a 5-day free trial—join now and save with the 25% OFF early bird discount . Enrollment is now open to the public! Topics include pharmacologic activity measurement, mechanisms of action, and GPCR discovery strategies. Take advantage of a 25% early bird discount for premium members! Topics cover new cellular assays, real-time kinetics, and unique GPCR behaviors. Secure your spot now by signing up today! Did you know...? As a  premium member , you can access over 500 minutes of exclusive, expert-led content from esteemed leaders, Drs. Kenakin and Hoare . We highly recommend exploring valuable resources such as ' Applying Pharmacology to Drug Discovery ' and ' Advanced Data Analysis for GPCR Pharmacology' ." GPCR Event Spotlight    11th Adhesion GPCR Workshop    Location:  Mexico City Dates:  October 23-25, 2024 Connect with peers and delve into cutting-edge adhesion GPCR biology. Interested in boosting your brand? Reach out to us at Hello@DrGPCR.com for sponsorship opportunities .  Let’s dive into the   Classified GPCR News  from August 19th to 25th, 2024 GPCR Activation and Signaling Homodimerization of CB2 cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling GPCR Binders, Drugs, and more Selenomethionine Promotes Milk Protein and Fat Synthesis and Proliferation of Mammary Epithelial Cells through the GPR37-mTOR-S6K1 Signaling GPCRs in Neuroscience Astrocyte Gi-GPCR signaling corrects compulsive-like grooming and anxiety-related behaviors in Sapap3 knockout mice Methods & Updates in GPCR Research Genome-wide identification of 769 G protein-coupled receptor (GPCR) genes from the marine medaka Oryzias melastigma Industry News Cumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery Project Ambrosia lands $16m to ‘improve on existing GLP-1 drugs’ Opening Ceremony of Xuzhou Zhongshu Research Site and CNS Drug Innovation Forum Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568 Call for GPCR Papers NEW Emerging Voices in GPCR Biology in Special Issue of Molecular Pharmacology GPCR Events, Meetings, and Webinars September 5 - 6, 2024 | 4th Transatlantic ECI GPCR Symposium September 18, 2024 | FREE Webinar - The value of GPCR cell-based assays in drug discovery NEW September 30 - October 3, 2024 | 22nd Discovery on Target October 2024 | Biologics US 2024   October 2 - 4, 2024 | 9th GPCRs in Medicinal Chemistry October 17, 2024 | Unprecedented fragment-based screening using Spectral Shift for GPCRs October 23 - 25, 2024 | 11th Adhesion GPCR Workshop November 5 - 7, 2024 | 16th Annual PEGS Europe   July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology GPCR Jobs NEW Research Associate Postdoc in GPCR mechanosensing   Postdoctoral Position Postdoctoral research position Senior or Lead Researcher   Become a Premium Member! Get your 5-day free trial TODAY!

lipopolysaccharide (LPS) and TNFα suggests that it may play a role in the development of inflammatory and fibrotic diseases

September 2022 β2-Adrenergic Receptor Expression and Intracellular Signaling in B Cells Are Highly Dynamic during Collagen-Induced Arthritis "The sympathetic nervous system (SNS) has either a pro-inflammatory or anti-inflammatory effect, depending on the stage of arthritis. In the past, treatment of arthritic B cells with a β2-adrenergic receptor (β2-ADR) agonist has been shown to attenuate arthritis. In this study, the expression and signaling of β2-ADR in B cells during collagen-induced arthritis (CIA) were investigated to provide an explanation of why only B cells from arthritic mice are able to improve CIA. Splenic B cells were isolated via magnetic-activated cell sorting (MACS). Adrenergic receptors on B cells and intracellular β2-ADR downstream molecules (G protein-coupled receptor kinase 2 (GRK-2), β-Arrestin 2, p38 MAPK, extracellular signal-regulated kinase 1/2 (ERK1/2) and cAMP response element-binding protein (CREB)) were analyzed at different time points in naïve and arthritic B cells with and without stimulation of β2-ADR agonist terbutaline by flow cytometry. β2-ADR-expressing B cells increase during CIA without a change in receptor density. Moreover, we observed a profound downregulation of GRK-2 shortly after induction of arthritis and an increase in β-Arrestin 2 only at late stage of arthritis. The second messengers studied (p38, ERK1/2 and CREB) followed a biphasic course, characterized by a reduction at onset and an increase in established arthritis. Stimulation of CIA B cells with the β-ADR agonist terbutaline increased pp38 MAPK independent of the timepoint, while pERK1/2 and pCREB were enhanced only in the late phase of arthritis. The phosphorylation of p38 MAPK, ERK1/2 and CREB in the late phase of arthritis was associated with increased IL-10 produced by B10 cells. The change of β2-ADR expression and signaling during sustained inflammation might be an integral part of the switch from pro- to anti-inflammatory action of sympathetic mechanisms in late arthritis." Read more at the source #DrGPCR #GPCR #IndustryNews

chemokine receptor system is implicated in a wide range of inflammatory, autoimmune and infectious diseases ; Poeta et al. 2019). extensively described the success and failure in drug discovery on chemokine receptors (Poeta et al. 2019 a single receptor as patients cannot be stratified into CKRs specific subpopulations for a specific disease the majority of potential therapeutic applications are situated in the area of chronic inflammatory disease